74608-26-7

Basic information

• Product Name: (1S)-1,2-Dimethyl-2-hydroxypropylamine, (2S)-2-Amino-3-hydroxy-3-methylbutane
• Synonyms: (1S)-1,2-Dimethyl-2-hydroxypropylamine, (2S)-2-Amino-3-hydroxy-3-methylbutane;(3S)-3-Amino-2-methylbutan-2-ol;(S)-3-Amino-2-methyl-butan-2-ol
• CAS NO: 74608-26-7
• Molecular Formula: C₅H₁₃NO
• Molecular Weight: 103.16282
• Mol File: 74608-26-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 178.2±13.0 °C(Predicted)
• Appearance: /
• Density: 0.915±0.06 g/cm3(Predicted)
• PKA: 13.01±0.50(Predicted)
• CAS DataBase Reference: (1S)-1,2-Dimethyl-2-hydroxypropylamine, (2S)-2-Amino-3-hydroxy-3-methylbutane(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-1,2-Dimethyl-2-hydroxypropylamine, (2S)-2-Amino-3-hydroxy-3-methylbutane(74608-26-7)
• EPA Substance Registry System: (1S)-1,2-Dimethyl-2-hydroxypropylamine, (2S)-2-Amino-3-hydroxy-3-methylbutane(74608-26-7)

Safety Data

• Hazardous Substances Data: 74608-26-7(Hazardous Substances Data)

Usage

General Description

The chemicals (1S)-1,2-Dimethyl-2-hydroxypropylamine and (2S)-2-Amino-3-hydroxy-3-methylbutane are both organic compounds. The (1S)-1,2-Dimethyl-2-hydroxypropylamine is a chiral amine with a hydroxy and a propyl group attached to the nitrogen atom, while the (2S)-2-Amino-3-hydroxy-3-methylbutane is a chiral amino alcohol with a hydroxy and a methyl group attached to the nitrogen atom. These compounds are commonly used as intermediates in the synthesis of pharmaceuticals, agrochemicals, and functional materials. Additionally, they can be used as chiral building blocks in organic chemistry due to their chiral nature, enabling the production of enantiomerically pure compounds for various applications in the chemical industry.

Upstream product

• 917-64-6 methyl magnesium iodide 
• 3082-75-5 L-Alanine ethyl ester 
• 6291-17-4 3-amino-2-methylbutan-2-ol 
• 449811-20-5 ((S)-2-hydroxy-1,2-dimethyl-propyl)carbamic acid tert-butyl ester 
• 75-65-0 tert-butyl alcohol 
• 1115-59-9 (S)-alanine ethyl ester hydrochloride 
• 74-88-4 methyl iodide 
• 1539314-81-2 (S)-3-(dibenzylamino)-2-methylbutan-2-ol 
• 75-16-1 methylmagnesium bromide 
• 2491-20-5 L-alanine methyl ester hydrochloride 

Downstream Products

• 563-80-4 3-methyl-butan-2-one 
• 24347-59-9 (S)-2-methylbutane-2,3-diol 
• 53399-77-2 (2R)-3-methyl-2,3-butanediol 
• 868136-51-0 S-3-[4-(4-fluoro-phenylamino)-pyrimidin-2-ylamino]-2-methyl-butan-2-ol 
• 898805-68-0 (S)-2-Methyl-3-(4-phenylamino-pyrimidin-2-ylamino)-butan-2-ol 
• 898799-79-6 (S)-3-[4-(4-Methoxy-phenylamino)-pyrimidin-2-ylamino]-2-methyl-butan-2-ol 
• 943787-02-8 C₃₆H₃₉N₃O₄ 
• 1105703-23-8 1-((1R,2S)-2-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidine-1-carbonyl)cyclopentyl)-3-((s)-3-hydroxy-3-methylbutan-2-yl)urea 
• 1427518-58-8 C₂₀H₂₇ClN₆O₂ 
• 1428631-13-3 (S)-5-((3-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 

Relevant articles and documents

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate

Carboxamide pyrazinyloxy benzoxaboroles were investigated with the goal to identify a molecule with satisfactory antimalarial activity, physicochemical properties, pharmacokinetic profile, in vivo efficacy, and safety profile. This optimization effort discovered 46, which met our target candidate profile. Compound 46 had excellent activity against cultured Plasmodium falciparum, and in vivo against P. falciparum and P. berghei in infected mice. It exhibited good PK properties in mice, rats, and dogs. It was highly active against the other 11 P. falciparum strains, which are mostly resistant to chloroquine and pyrimethamine. The rapid parasite in vitro reduction and in vivo parasite clearance profile of 46 were similar to those of artemisinin and chloroquine, two rapid-acting antimalarials. It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg. The combined properties of this novel benzoxaborole support its progression to preclinical development.

CYCLIC UREA INHIBITORS OF HB-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell Or the inhibition of the conversion of cortisone to Cortisol in a cell.

Tri-substituted ureas as cytokine inhibitors

The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to c